Stockreport

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution [Yahoo! Finance]

Matinas Biopharma Holdings, Inc.  (MTNB) 
NASDAQ:AMEX Investor Relations: ir.matinasbiopharma.com
PDF All 5 patients who completed the desired course of treatment had complete clinical resolution of their infection; patients with ongoing treatment continue to experience [Read more]